- Home
- AYI vs ROIV Comparison
AYI vs ROIV Comparison
Compare AYI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AYI | ROIV |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AYI | ROIV |
|---|---|---|
| Price | $363.51 | $21.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $395.17 | $21.94 |
| AVG Volume (30 Days) | 225.1K | ★ 6.5M |
| Earning Date | 01-08-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 12.53 | N/A |
| Revenue | ★ $4,345,600,000.00 | $20,329,000.00 |
| Revenue This Year | $10.92 | N/A |
| Revenue Next Year | $5.15 | $376.94 |
| P/E Ratio | $29.90 | ★ N/A |
| Revenue Growth | ★ 13.14 | N/A |
| 52 Week Low | $216.81 | $8.73 |
| 52 Week High | $379.17 | $22.45 |
Technical Indicators
Market Signals| Indicator | AYI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 68.21 |
| Support Level | $367.77 | $20.14 |
| Resistance Level | $377.15 | $21.48 |
| Average True Range (ATR) | 9.75 | 0.66 |
| MACD | 0.57 | -0.02 |
| Stochastic Oscillator | 49.72 | 87.12 |
Price Performance
Historical ComparisonAbout AYI Acuity Brands Inc.
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. Acuity, Inc. designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity, Inc. has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.